Literature DB >> 29188489

Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?

Richard Hoffmann1,2,3, Callum Logan4, Michael O'Callaghan4,5, Kirsten Gormly6, Ken Chan6, Darren Foreman4,7.   

Abstract

INTRODUCTION: Multiparametric MRI (mpMRI) is useful in detecting anterior prostate tumours. Due to the location of anterior tumours, they are often diagnosed with a large size and may be suspicious for extra-prostatic extension (EPE). We aim to evaluate whether PI-RADS v2 is more accurate in assessing anterior prostate lesions identified on mpMRI compared to PI-RADS v1.
METHODS: Patients with anterior prostate lesions diagnosed on mpMRI who proceeded to a cognitive fusion transperineal prostate biopsy were identified. Each mpMRI was blinded and read by two experienced prostate MRI radiologists and assigned a PI-RADS v1 and PI-RADS v2 score, and the presence of EPE was estimated. Correlation was made with transperineal histopathology and, where relevant, radical prostatectomy histopathology. Concordance measures between PI-RADS v1 and PI-RADS v2, and between examiners of the same PI-RADS score were calculated using a weighted kappa.
RESULTS: Fifty-eight consecutive men were identified. Concordance between the examiners for PI-RADS v1 and for v2 showed substantial agreement (version 1: weighted kappa 0.71; version 2: weighted kappa 0.69). There was no difference in accuracy when using PI-RADS v1 or PI-RADS v2 to predict clinically significant cancer. There was poor correlation between EPE measured on mpMRI compared with EPE in radical prostatectomy histopathology.
CONCLUSION: PI-RADS v2 is reproducible between radiologists but does not have improved accuracy for diagnosing anterior tumours of the prostate when compared to PI-RADS v1. Multiparametric MRI is accurate at detecting anterior tumours with a sensitivity of 86-88%.

Entities:  

Keywords:  Anterior tumours; MRI; Multiparametric; PI-RADS; Prostate cancer

Mesh:

Year:  2017        PMID: 29188489     DOI: 10.1007/s11255-017-1753-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

1.  Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.

Authors:  Christopher Lim; Trevor A Flood; Shaheed W Hakim; Wael M Shabana; Jeffrey S Quon; Mohamed El-Khodary; Rebecca E Thornhill; Soufiane El Hallani; Nicola Schieda
Journal:  J Magn Reson Imaging       Date:  2015-08-25       Impact factor: 4.813

2.  Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard.

Authors:  L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

3.  Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.

Authors:  Dmitry Volkin; Baris Turkbey; Anthony N Hoang; Soroush Rais-Bahrami; Nitin Yerram; Annerleim Walton-Diaz; Jeffrey W Nix; Bradford J Wood; Peter L Choyke; Peter A Pinto
Journal:  BJU Int       Date:  2014-10-18       Impact factor: 5.588

4.  Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading.

Authors:  Adil Ouzzane; Philippe Puech; Laurent Lemaitre; Xavier Leroy; Pierre Nevoux; Nacim Betrouni; Georges-Pascal Haber; Arnauld Villers
Journal:  Urology       Date:  2011-08-16       Impact factor: 2.649

5.  Evaluation of MRI for diagnosis of extraprostatic extension in prostate cancer.

Authors:  Satheesh Krishna; Christopher S Lim; Matthew D F McInnes; Trevor A Flood; Wael M Shabana; Robert S Lim; Nicola Schieda
Journal:  J Magn Reson Imaging       Date:  2017-04-07       Impact factor: 4.813

6.  Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Authors:  Caroline M A Hoeks; Martijn G Schouten; Joyce G R Bomers; Stefan P Hoogendoorn; Christina A Hulsbergen-van de Kaa; Thomas Hambrock; Henk Vergunst; J P Michiel Sedelaar; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Eur Urol       Date:  2012-02-01       Impact factor: 20.096

7.  Assessment of PI-RADS v2 for the Detection of Prostate Cancer.

Authors:  Moritz Kasel-Seibert; Thomas Lehmann; René Aschenbach; Felix V Guettler; Mohamed Abubrig; Marc-Oliver Grimm; Ulf Teichgraeber; Tobias Franiel
Journal:  Eur J Radiol       Date:  2016-01-19       Impact factor: 3.528

8.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

9.  'Prostatic evasive anterior tumours': the role of magnetic resonance imaging.

Authors:  Nathan Lawrentschuk; Masoom A Haider; Nikhil Daljeet; Andrew Evans; Ants Toi; Antonio Finelli; John Trachtenberg; Alexandre Zlotta; Neil Fleshner
Journal:  BJU Int       Date:  2009-10-08       Impact factor: 5.588

10.  Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings.

Authors:  Laurent Lemaitre; Philippe Puech; Edouard Poncelet; Sébastien Bouyé; Xavier Leroy; Jacques Biserte; Arnauld Villers
Journal:  Eur Radiol       Date:  2008-08-29       Impact factor: 5.315

View more
  6 in total

1.  Observed racial disparity in the negative predictive value of multi-parametric MRI for the diagnosis for prostate cancer.

Authors:  Amr Mahran; Kirtishri Mishra; Laura Bukavina; Fredrick Schumacher; Anna Quian; Christina Buzzy; Carvell T Nguyen; Vikas Gulani; Lee E Ponsky
Journal:  Int Urol Nephrol       Date:  2019-05-02       Impact factor: 2.370

2.  Prediction of extraprostatic extension on multi-parametric magnetic resonance imaging in patients with anterior prostate cancer.

Authors:  Hyungwoo Ahn; Sung Il Hwang; Hak Jong Lee; Hyoung Sim Suh; Gheeyoung Choe; Seok-Soo Byun; Sung Kyu Hong; Sangchul Lee; Joongyub Lee
Journal:  Eur Radiol       Date:  2019-08-05       Impact factor: 5.315

3.  Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer.

Authors:  Mou Li; Ling Yang; Yufeng Yue; Jingxu Xu; Chencui Huang; Bin Song
Journal:  Front Oncol       Date:  2021-02-17       Impact factor: 6.244

4.  Structured reporting in radiologic education - Potential of different PI-RADS versions in prostate MRI controlled by in-bore MR-guided biopsies.

Authors:  Marietta Garmer; Julia Karpienski; Dietrich Hw Groenemeyer; Birgit Wagener; Lars Kamper; Patrick Haage
Journal:  Br J Radiol       Date:  2021-12-16       Impact factor: 3.039

5.  Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review.

Authors:  Armando Stabile; Francesco Giganti; Veeru Kasivisvanathan; Gianluca Giannarini; Caroline M Moore; Anwar R Padhani; Valeria Panebianco; Andrew B Rosenkrantz; Georg Salomon; Baris Turkbey; Geert Villeirs; Jelle O Barentsz
Journal:  Eur Urol Oncol       Date:  2020-03-17

6.  Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation.

Authors:  Sonia Gaur; Nathan Lay; Stephanie A Harmon; Sreya Doddakashi; Sherif Mehralivand; Burak Argun; Tristan Barrett; Sandra Bednarova; Rossanno Girometti; Ercan Karaarslan; Ali Riza Kural; Aytekin Oto; Andrei S Purysko; Tatjana Antic; Cristina Magi-Galluzzi; Yesim Saglican; Stefano Sioletic; Anne Y Warren; Leonardo Bittencourt; Jurgen J Fütterer; Rajan T Gupta; Ismail Kabakus; Yan Mee Law; Daniel J Margolis; Haytham Shebel; Antonio C Westphalen; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Ronald M Summers; Baris Turkbey
Journal:  Oncotarget       Date:  2018-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.